INTERLEUKIN-6, a potent pro-inflammatory cytokine, might be involved in Behet's disease (BD) pathological pathways. We investigated IL-6 levels in sera and synovial fluids collected from BD patients. The IL-6 production was also studied in vivo, by measuring its activity in culture supernatants of PBMC and alveolar macrophages, stimulated or not with LPS. The patients with BD were compared to RA patients and healthy controls. High IL-6 levels were observed in sera, synovial fluid and LPSstimulated PBMC supernatants, from active BD patients, similar to those of RA patients. Alveolar macrophages production of IL-6 was significantly elevated in two active BD patients with an interstitial pneumonia, when compared to controls. These elevated levels of IL-6 suggest its involvement in the inflammatory sites of BD, which may be related to the progression of the acute lesions, at least in the joints and in the lungs.
Introduction
Behet's disease (BD) is a multisystemic disease, mainly observed in Mediterranean areas and in Japan; it is characterized by oral and genital ulcerations, associated with ocular and skin lesions, arthralgia, neurological involvement, and pulmonary manifestations.
Elevated levels of interleukin-1 (IL-1), tumour necrosis factor-(TNF-), soluble interleukin-2 receptor 2 and gamma-interferon 3-s have been observed in patients with active Behet's disease (BD), suggesting the involvement of these cytokines in the inflammatory process.
Among the immunological factors that have been recently involved in the inflammatory manifestations, interleukin-6 (IL-6) plays a prominent role. 6 IL-6 has pleitropic biological effects, including human T-cell activation, 7 and B-cell proliferation and differentiation.
The aim of our study was to evaluate in BD patients IL-6 level in sera and IL-6 production by blood mononuclear cells (PBMC) into culture supernatants. Moreover, to inactive BD and control subjects (p < 0.01).
There was no dierence in spontaneous production between patients with inactive BD and healthy controls.
After LPS stimulation IL-6 production was significantly increased (p < 0.01) in patients with active BD (2980 518 U ml-1), in inactive BD patients (2390 __+ 310 U ml-1), and in RA patients (2950-t-873 U m1-1) (Fig. 2) as compared with healthy controls (1100 -t-117 U ml-1). whereas IL-6 is normally detected in the circulation, and rises rapidly after even minor trauma and inflammation. 23 IFN-2 and IL-6 are known to interact either synergistically or antagonistically. In active BD, the release of gamma-interferon (IFN-),) is increased. 4'5 It may be responsible for the enhancement of IL-6 production. 24 On the other hand, IL-6 may accelerate the inflammatory reaction by stimulating T-and B-cells, leading to further IFN-) production. 24 Our aim in investigating in vitro and in vivo IL-6 production, was to study the cell-cell interactions that are influenced in a positive or 
